These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 1866206)
1. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions. Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206 [TBL] [Abstract][Full Text] [Related]
2. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture. Johnston WW Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301 [TBL] [Abstract][Full Text] [Related]
3. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions. Bassarova AV; Nesland JM; Davidson B Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331 [TBL] [Abstract][Full Text] [Related]
4. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions. Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575 [TBL] [Abstract][Full Text] [Related]
5. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma. Delahaye M; Hoogsteden HC; Van der Kwast TH J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800 [TBL] [Abstract][Full Text] [Related]
6. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
7. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions]. Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134 [TBL] [Abstract][Full Text] [Related]
8. Use of a monoclonal antibody (B72.3) as an immunocytochemical adjunct to diagnosis of adenocarcinoma in human effusions. Johnston WW; Szpak CA; Lottich SC; Thor A; Schlom J Cancer Res; 1985 Apr; 45(4):1894-900. PubMed ID: 3884146 [TBL] [Abstract][Full Text] [Related]
9. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Szpak CA; Johnston WW; Lottich SC; Kufe D; Thor A; Schlom J Acta Cytol; 1984; 28(4):356-67. PubMed ID: 6205527 [TBL] [Abstract][Full Text] [Related]
10. [GC12, marker of cells of mesodermal origin. Value and application to cytodiagnosis of serous effusions]. Daste G; Gioanni J; Lauque D; Kremps M; Mazeau C; Paquis P; Schneider M Arch Anat Cytol Pathol; 1997; 45(4):185-91. PubMed ID: 9406475 [TBL] [Abstract][Full Text] [Related]
12. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Shield PW; Koivurinne K Cytopathology; 2008 Aug; 19(4):218-23. PubMed ID: 17916095 [TBL] [Abstract][Full Text] [Related]
13. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Afify AM; Stern R; Michael CW Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337 [TBL] [Abstract][Full Text] [Related]
14. Immunocytochemical identification of carcinomas of unknown primary in serous effusions. Pomjanski N; Grote HJ; Doganay P; Schmiemann V; Buckstegge B; Böcking A Diagn Cytopathol; 2005 Nov; 33(5):309-15. PubMed ID: 16240395 [TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Maguire B; Whitaker D; Carrello S; Spagnolo D Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591 [TBL] [Abstract][Full Text] [Related]
16. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1]. Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046 [TBL] [Abstract][Full Text] [Related]
17. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions. Conner JR; Cibas ES; Hornick JL; Qian X Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880 [TBL] [Abstract][Full Text] [Related]
18. Cytological study of serous effusions with the aid of tumour markers. Ray K; Mittal S; Gupta H; Jain M J Indian Med Assoc; 1999 Jan; 97(1):11-2, 19. PubMed ID: 10549179 [TBL] [Abstract][Full Text] [Related]
19. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Davidson B; Baekelandt M; Shih IeM Diagn Cytopathol; 2007 Dec; 35(12):756-60. PubMed ID: 18008338 [TBL] [Abstract][Full Text] [Related]
20. Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases. Davidson B; Dong HP; Berner A; Christensen J; Nielsen S; Johansen P; Bryne M; Asschenfeldt P; Risberg B Am J Clin Pathol; 2002 Jul; 118(1):85-92. PubMed ID: 12109861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]